Drug Topics

NOVEMBER 6, 2023

Although long COVID has emerged as a major public health concern, it has not yet been clearly identified as a clinical condition.

265

265

Pharmacy Times

NOVEMBER 6, 2023

AI is expected to significantly quicken the pace of drug design and development, while improving the success rate of new medicines.

176

176

Drug Topics

NOVEMBER 6, 2023

Unlike traditional THC, which is federally banned, D8 has managed to find a legal loophole, making it widely accessible.

187

187

Pharmacy Times

NOVEMBER 6, 2023

Children with a score of higher than 30 on the CHALF Score scale will need an emergency transplant.

158

158

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

STAT

NOVEMBER 6, 2023

When Christian Pulcini was a pediatric emergency fellow at Children’s Hospital of Philadelphia, he witnessed firsthand the ways that gun violence affected children who survived it. He still remembers one young boy who had been shot in the neck while playing outside his home. Pulcini did not remove the bullet — a routine practice, often safer than removal.

Hospitals 144

Hospitals 144

Pharmacy Times

NOVEMBER 6, 2023

Pharmacists can play a vital role in educating patients about headaches and can help to limit their impact on the patient.

145

145

Pharmacy Times

NOVEMBER 6, 2023

A low carbohydrate diet plus a sodium glucose contransporter-2 (SGLT2) inhibitor was found to be safe and effective for weight loss and glycemic control in patients with diabetes and chronic kidney disease.

139

139

STAT

NOVEMBER 6, 2023

Harm reduction is having its moment in America. The doors of drug-related harm reduction have swung wide open after years of federal funding bans. Extensive opioid settlement payouts combined with an urgency to address the overdose crisis have allowed for harm reduction approaches to catch on like wildfire. But as renowned addiction author William White muses, “The fastest way to kill anything in America is to turn it into a superficial fad that dies from distortion and over-exposure.

142

142

Pharmacy Times

NOVEMBER 6, 2023

Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.

139

139

BioPharm

NOVEMBER 6, 2023

The Alliance for mRNA Medicines (AMM) was officially launched at the 11th International mRNA Health Conference in Berlin, Germany.

133

133

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Healthcare

NOVEMBER 6, 2023

Medicare Advantage (MA) beneficiaries have better quality of care and health outcomes than traditional fee-for-service counterparts, researchers from Harvard Medical School found. | Another white paper released by Inovalon and Harvard Medical School highlights the benefits Medicare Advantage enrollees enjoy over traditional Medicare counterparts.

Medical Schools 132

Medical Schools Hospitals 132

Pharmacy Times

NOVEMBER 6, 2023

Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.

132

132

STAT

NOVEMBER 6, 2023

Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value of life-saving cystic fibrosis medicines. In draft guidance published late last week, the National Institute for Health and Care Excellence stated that a groundbreaking treatment called Trikafta and two other cystic fibrosis medications sold by the company offer notable clinical benefits, but are not cost-effective.

132

132

pharmaphorum

NOVEMBER 6, 2023

How over-investment is killing digital health companies Mike.

128

128

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

NOVEMBER 6, 2023

The fast-evolving world of digital therapeutics offers the promise of lowering barriers to accessing health care, but the companies behind these software-based tools face an uphill battle in convincing clinicians and insurers that their products can complement traditional medicine. That debate has largely focused on the quality of evidence backing these prescription digital therapies.

Insurance 131

Insurance FDA 131

Fierce Pharma

NOVEMBER 6, 2023

History may repeat for Vertex Pharmaceuticals in the U.K., where a new decision by the country’s cost-effectiveness gatekeeper threatens to spark another dispute over the cost of lifesaving cystic | Last week, the U.K.'s National Institute for Health and Care Excellence unveiled draft guidance that acknowledged the effectiveness of Vertex’s cystic fibrosis drugs Trikafta, Symkevi and Orkambi.

Labelling 124

Labelling 124

STAT

NOVEMBER 6, 2023

Astellas on Saturday presented study results showing an increased treatment effect over time for its approved medicine for a common type of vision loss. The new data are probably enough to convince the Food and Drug Administration to remove restrictions on the drug’s use, but they still don’t measure up to a competing treatment from Apellis Pharmaceuticals.

129

129

Pharmacy Times

NOVEMBER 6, 2023

Treatment options for individuals impacted with PMS can vary and include lifestyle modifications, medication treatments, and herbal products.

123

123

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

NOVEMBER 6, 2023

The federal government is proposing to rein in health insurance companies that entice brokers with lavish bonuses to sell their Medicare Advantage plans by placing a firmer cap on broker compensation. However, even with new guardrails in place, agents and brokers will still have strong financial incentives to move people into Medicare Advantage plans instead of pitching supplemental coverage for the traditional Medicare program.

Health Insurance Companies 125

Health Insurance Companies Insurance 125

Fierce Pharma

NOVEMBER 6, 2023

As Vertex preps for exa-cel launch, exec touts 'very large' opportunity but tempers early expectations zbecker Mon, 11/06/2023 - 20:59

122

122

STAT

NOVEMBER 6, 2023

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%. That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development.

124

124

pharmaphorum

NOVEMBER 6, 2023

Anthropy23, part one: The future of AI, the future of Britain Mike.

122

122

Fierce Pharma

NOVEMBER 6, 2023

At the start of its first-ever conference call to present its quarterly numbers, Krystal Biotech CEO Krish Krishnan was quick to point out that the company’s positive earnings for the third quarter | Krystal Biotech's launch of Vyjuvek, the world's first topical gene therapy, has been so promising that analysts with Evercore ISI increased their 2024 sales projection to $273 million.

FDA 119

FDA 119

pharmaphorum

NOVEMBER 6, 2023

Drug combos from AZ, Boehringer show promise in CKD Phil.

121

121

Fierce Healthcare

NOVEMBER 6, 2023

Cigna is looking into the possibility of selling its Medicare Advantage (MA) business, according to a report from Reuters. | Cigna may decide to sell off its Medicare Advantage business. The insurer is reportedly in early discussions with an investment bank to go over its options.

Insurance 119

Insurance 119

pharmaphorum

NOVEMBER 6, 2023

UK patient data project reaches one million volunteers Phil.

119

119

Fierce Healthcare

NOVEMBER 6, 2023

Kaiser Permanente pulled in $239 million in net income during the third quarter of 2023, a turnaround from the $1.5 billion net loss the integrated system had seen a year prior. | The massive integrated nonprofit's $156 million operating income turns around the $75 million operating loss of the third quarter of 2022 but is a slight pullback from 2023's prior quarters.

116

116

Fierce Pharma

NOVEMBER 6, 2023

After this summer’s FDA approval of Iveric Bio’s Izervay—the drug at the center of the $5.9 billion buyout by Japanese pharma Astellas—the battle for the geographic atrophy (GA) crown is on in the | After this summer’s approval of Iveric Bio’s Izervay—the drug at the center of the $5.9 billion buyout by Japanese pharma Astellas—the battle for the geographic atrophy crown is on in the U.S.

FDA 115

FDA 115

Drug Store News

NOVEMBER 6, 2023

Inspired by the rustic allure of a cozy cabin retreat, the line’s color palette draws inspiration from the serene beauty of a vintage winter wonderland, the brand stated.

115

115

Fierce Pharma

NOVEMBER 6, 2023

Following suit with other companies that produce COVID-19 vaccines, BioNTech has discovered demand for its Pfizer-partnered, omicron-adapted shot has not met expectations this fall and has had to a | BioNTech has slashed its estimate of 2023 revenue by 20%, now expecting it to reach 4 billion euros ($4.3 billion) versus its previous estimate of 5 billion euros ($5.4 billion).

Vaccines 114

Vaccines 114

pharmaphorum

NOVEMBER 6, 2023

Bayer doubles down on Factor XIa with new phase 3 trial Phil.

113

113

Drug Store News

NOVEMBER 6, 2023

Three OTC hearing aids are now available at more than 1,000 locations across 39 states, with select models also available for purchase online.

111

111

The Checkup by Singlecare

NOVEMBER 6, 2023

Those on immunosuppressive drugs for psoriasis or ulcerative colitis may soon breathe a little easier when they get to the pharmacy counter: The U.S. Food and Drug Administration (FDA) just approved Wezlana (ustekinumab-auub), a biosimilar for the popular drug Stelara. Manufactured by Amgen, the biosimilar—which is like a generic for biologic medications—was approved to treat inflammatory conditions like plaque psoriasis or ulcerative colitis.

FDA 110

FDA Immunization 110